NCT05229588 2025-08-15
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
HonorHealth Research Institute
Phase 2 Completed
Clinical Trials
7 trialsNCT02454972 2023-03-02
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
Phase 2 Completed
NCT03213301 2021-07-14
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
Phase 2 Completed
NCT02448537 2021-03-03
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT01525589 2020-09-25
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
PharmaMar
Phase 2 Completed
NCT02451007 2019-11-19
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
Phase 2 Completed
NCT01951157 2019-09-24
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
PharmaMar
Phase 2 Completed